#USA #New York #Pomerantz LLP #Fortress Biotech #FBIO

Pomerantz Law Firm Investigates Fortress Biotech Inc. for Potential Securities Fraud

In a significant move for investors, Pomerantz LLP has announced its investigation into Fortress Biotech Inc., listed on NASDAQ under the ticker symbol FBIO. The investigative firm, renowned for its expertise in class actions related to corporate and securities fraud, aims to determine whether Fortress or its officials have been involved in any unlawful business practices or securities fraud.

The alarm bells were raised when Fortress Biotech, alongside its subsidiary Cyprium Therapeutics, made a crucial announcement on October 1, 2025. According to their statement, the company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding their New Drug Application for CUTX-101. This letter indicated notable deficiencies in compliance with Current Good Manufacturing Practices (cGMP) observed at the facility responsible for the production of CUTX-101. Such regulatory hurdles are highly detrimental in the pharmaceutical industry, leading to concerns over product viability and ultimately investor trust.

In response to this adverse development, the company's stock price experienced a dramatic drop. Fortress Biotech's shares plummeted by $1.14, marking a staggering decline of 30.81%, closing at $2.56 per share on the same day the announcement was made. For investors, this sharp decline may signify deeper issues at the company that could potentially impact their investments significantly.

Pomerantz LLP is reaching out to investors affected by this sudden decline and is urging them to come forward. Interested parties are encouraged to contact Danielle Peyton via email at [email protected] or by phone at 646-581-9980, ext. 7980. Joining this investigation could allow investors to participate in a class action if the findings validate their concerns about Fortress Biotech’s practices.

Founded by Abraham L. Pomerantz, often referred to as the dean of the class action bar, Pomerantz LLP holds a prestigious reputation for representing victims of corporate misconduct. Over its 85 years in operation, the firm has secured numerous multimillion-dollar awards for those defrauded in securities transactions. Their commitment to defending investor rights ensures that they remain at the forefront of securities litigation, fighting for accountability and justice against corporations that may have violated shareholder trust.

As the investigation unfolds, Fortress Biotech investors may find themselves in a precarious position, weighing the risks associated with their investments amidst allegations of potential securities fraud. Heightened scrutiny from regulatory bodies such as the FDA, combined with legal investigations from firms like Pomerantz, paints a troubling picture for the future of Fortress Biotech.

Additional Resources

For more information, you can visit Pomerantz's official website at www.pomlaw.com, which provides insights into their past successes and ongoing cases. This could serve as a valuable resource for investors seeking further clarity on their potential courses of action concerning their investments in Fortress Biotech.